Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis
Open Access
- 27 August 2026
- journal article
- research article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 15 (S1) , 49-60
Abstract
No abstract availableKeywords
Funding Information
- Envision Pharma Group
This publication has 19 references indexed in Scilit:
- Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with TafamidisEuropean Journal of Heart Failure, 2025
- Early Access to Tafamidis for Patients With Transthyretin Amyloid CardiomyopathyJACC: Advances, 2025
- Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic BenefitsCardiology and Therapy, 2025
- Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOSCardiology and Therapy, 2025
- Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stageEuropean Journal of Heart Failure, 2025
- Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Journal of Cardiac Failure, 2024
- Screening for Transthyretin Amyloid Cardiomyopathy in Everyday PracticeJACC: Heart Failure, 2019
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Transthyretin-related amyloidoses and the heart: a clinical overviewNature Reviews Cardiology, 2010